Amid the growing importance of pneumococcal vaccination to prevent pneumonia during the change of seasons, confusion is ...

Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays ...

The 23-valent pneumococcal polysaccharide vaccine (PPSV23) has completed the on-site work for Phase III clinical trials and ...

The 23-valent pneumococcal polysaccharide vaccine (PPSV23) has completed the on-site work for Phase III clinical trials and plans to submit a pre-application for market registration to the National ...

“The happiness index changes after a certain age,” said secretary Arup Sinha. For seniors, wellness is about staying engaged ...

Merck’s Capvaxive receives European approval for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults: Rahway, New Jersey Friday, March 28, 2025, 09: ...

MSD has received approval from the EC for Capvaxive, a pneumococcal 21-valent conjugate vaccine, to prevent invasive disease ...

Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and ...

The STRIDE-10 trial compared the vaccine to pneumococcal vaccine, polyvalent [23-valent] (PPSV23) in those aged 50 years and above. The approval was further supported by outcomes from the Phase ...

The data, however, do not reflect the comparative efficacy of the vaccines. The STRIDE clinical program included several Phase 3 trials which demonstrated that CAPVAXIVE was non-inferior or superior ...